Free Trial
NYSE:ADCT

ADC Therapeutics (ADCT) Stock Price, News & Analysis

ADC Therapeutics logo
$2.93 0.00 (0.00%)
(As of 11/8/2024 ET)

About ADC Therapeutics Stock (NYSE:ADCT)

Key Stats

Today's Range
$2.92
$3.07
50-Day Range
$2.70
$3.33
52-Week Range
$0.36
$6.04
Volume
213,577 shs
Average Volume
367,514 shs
Market Capitalization
$283.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.25
Consensus Rating
Buy

Company Overview

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADC Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
47th Percentile Overall Score

ADCT MarketRank™: 

ADC Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 612th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ADC Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ADC Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about ADC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for ADC Therapeutics are expected to grow in the coming year, from ($1.72) to ($1.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ADC Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ADC Therapeutics is -1.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about ADC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.63% of the outstanding shares of ADC Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    ADC Therapeutics has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in ADC Therapeutics has recently decreased by 1.40%, indicating that investor sentiment is improving.
  • Dividend Yield

    ADC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    ADC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.63% of the outstanding shares of ADC Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    ADC Therapeutics has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in ADC Therapeutics has recently decreased by 1.40%, indicating that investor sentiment is improving.
  • News Sentiment

    ADC Therapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for ADCT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ADC Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of ADC Therapeutics is held by insiders.

  • Percentage Held by Institutions

    41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ADC Therapeutics' insider trading history.
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADCT Stock News Headlines

ADC Therapeutics Highlights Q3 Advances and Strategic Focus
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
ADC Therapeutics's Earnings: A Preview
See More Headlines

ADCT Stock Analysis - Frequently Asked Questions

ADC Therapeutics' stock was trading at $1.66 at the beginning of the year. Since then, ADCT shares have increased by 76.5% and is now trading at $2.93.
View the best growth stocks for 2024 here
.

ADC Therapeutics SA (NYSE:ADCT) announced its earnings results on Tuesday, August, 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. The business had revenue of $17.41 million for the quarter, compared to analyst estimates of $19.06 million.

ADC Therapeutics (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

Top institutional investors of ADC Therapeutics include SG Americas Securities LLC (0.03%) and Intech Investment Management LLC (0.01%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby.
View institutional ownership trends
.

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/06/2024
Today
11/10/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/12/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
310
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.25
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+181.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-240,050,000.00
Net Margins
-323.60%
Pretax Margin
-249.82%

Debt

Sales & Book Value

Annual Sales
$69.56 million
Book Value
($1.93) per share

Miscellaneous

Free Float
92,724,000
Market Cap
$283.30 million
Optionable
Optionable
Beta
1.59
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NYSE:ADCT) was last updated on 11/10/2024 by MarketBeat.com Staff
From Our Partners